In IBD specifically, pharmacological or dietary activation of Nrf2 may complement conventional immunosuppressive therapies by reinforcing the mucosal antioxidant shield and breaking the vicious cycle of oxidative stress and immune activation [94,95]. Here, NFE2L2 is linked to inflammatory bowel disease.